MX2019014876A - Compuestos heteroaromaticos como inhibidores de vanina. - Google Patents
Compuestos heteroaromaticos como inhibidores de vanina.Info
- Publication number
- MX2019014876A MX2019014876A MX2019014876A MX2019014876A MX2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A MX 2019014876 A MX2019014876 A MX 2019014876A
- Authority
- MX
- Mexico
- Prior art keywords
- heteroaromatic compounds
- compounds
- vanin
- inhibitors
- vanin inhibitors
- Prior art date
Links
- 150000002390 heteroarenes Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención abarca los compuestos de la Fórmula (I) (ver Fórmula) en donde los grupos A y B se definen en la presente, que son adecuados para el tratamiento de enfermedades relacionadas con vanina, y los procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518106P | 2017-06-12 | 2017-06-12 | |
| PCT/EP2018/065140 WO2018228934A1 (en) | 2017-06-12 | 2018-06-08 | Heteroaromatic compounds as vanin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014876A true MX2019014876A (es) | 2020-02-13 |
Family
ID=62631060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014876A MX2019014876A (es) | 2017-06-12 | 2018-06-08 | Compuestos heteroaromaticos como inhibidores de vanina. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10364255B2 (es) |
| EP (1) | EP3638680B1 (es) |
| JP (1) | JP6880243B2 (es) |
| KR (1) | KR102607934B1 (es) |
| CN (1) | CN110770242B (es) |
| AR (1) | AR112086A1 (es) |
| AU (1) | AU2018285131B2 (es) |
| BR (1) | BR112019021703A2 (es) |
| CA (1) | CA3066946A1 (es) |
| CL (1) | CL2019003515A1 (es) |
| CO (1) | CO2019013823A2 (es) |
| DK (1) | DK3638680T3 (es) |
| EA (1) | EA039223B1 (es) |
| ES (1) | ES2927021T3 (es) |
| HU (1) | HUE060597T2 (es) |
| IL (1) | IL271104B (es) |
| MA (1) | MA49374A (es) |
| MX (1) | MX2019014876A (es) |
| PE (1) | PE20200340A1 (es) |
| PH (1) | PH12019502693A1 (es) |
| PL (1) | PL3638680T3 (es) |
| TW (1) | TWI855993B (es) |
| WO (1) | WO2018228934A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP6880243B2 (ja) * | 2017-06-12 | 2021-06-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | バニン阻害薬としてのヘテロ芳香族化合物 |
| UA127629C2 (uk) | 2018-08-13 | 2023-11-08 | Ф. Хоффманн-Ля Рош Аг | Нові гетероциклічні сполуки як інгібітори моноацилгліцеролліпази |
| US10864201B2 (en) * | 2018-08-28 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| CR20210294A (es) | 2018-12-03 | 2021-08-13 | Boehringer Ingelheim Int | Compuestos heteroaromáticos como inhibidores de vanina |
| CA3120037A1 (en) | 2018-12-03 | 2020-06-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as vanin inhibitors |
| WO2021048242A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005035524A1 (en) * | 2003-10-09 | 2005-04-21 | Abbott Laboratories | Pyrrolidinyl urea derivatives as angiogensis inhibitors |
| EP3303303A1 (en) * | 2015-05-29 | 2018-04-11 | Pfizer Inc | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| MA45656A (fr) * | 2016-07-14 | 2021-03-24 | Pfizer | Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 |
| JP6880243B2 (ja) * | 2017-06-12 | 2021-06-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | バニン阻害薬としてのヘテロ芳香族化合物 |
-
2018
- 2018-06-08 JP JP2019566724A patent/JP6880243B2/ja active Active
- 2018-06-08 CA CA3066946A patent/CA3066946A1/en active Pending
- 2018-06-08 MX MX2019014876A patent/MX2019014876A/es unknown
- 2018-06-08 MA MA049374A patent/MA49374A/fr unknown
- 2018-06-08 ES ES18731766T patent/ES2927021T3/es active Active
- 2018-06-08 CN CN201880039562.3A patent/CN110770242B/zh active Active
- 2018-06-08 EA EA202090014A patent/EA039223B1/ru unknown
- 2018-06-08 PL PL18731766.4T patent/PL3638680T3/pl unknown
- 2018-06-08 BR BR112019021703-7A patent/BR112019021703A2/pt unknown
- 2018-06-08 EP EP18731766.4A patent/EP3638680B1/en active Active
- 2018-06-08 US US16/003,252 patent/US10364255B2/en active Active
- 2018-06-08 HU HUE18731766A patent/HUE060597T2/hu unknown
- 2018-06-08 PE PE2019002531A patent/PE20200340A1/es unknown
- 2018-06-08 DK DK18731766.4T patent/DK3638680T3/da active
- 2018-06-08 WO PCT/EP2018/065140 patent/WO2018228934A1/en active Application Filing
- 2018-06-08 KR KR1020197038628A patent/KR102607934B1/ko active Active
- 2018-06-08 AU AU2018285131A patent/AU2018285131B2/en active Active
- 2018-06-11 AR ARP180101573A patent/AR112086A1/es unknown
- 2018-06-11 TW TW107119946A patent/TWI855993B/zh active
-
2019
- 2019-05-13 US US16/410,037 patent/US20190263828A1/en not_active Abandoned
- 2019-11-28 PH PH12019502693A patent/PH12019502693A1/en unknown
- 2019-12-02 IL IL271104A patent/IL271104B/en unknown
- 2019-12-02 CL CL2019003515A patent/CL2019003515A1/es unknown
- 2019-12-09 CO CONC2019/0013823A patent/CO2019013823A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018228934A1 (en) | 2018-12-20 |
| JP6880243B2 (ja) | 2021-06-02 |
| IL271104A (en) | 2020-01-30 |
| CL2019003515A1 (es) | 2020-06-19 |
| US20190263828A1 (en) | 2019-08-29 |
| CN110770242B (zh) | 2022-08-19 |
| EA039223B1 (ru) | 2021-12-20 |
| AU2018285131A1 (en) | 2019-10-31 |
| EP3638680B1 (en) | 2022-08-10 |
| TWI855993B (zh) | 2024-09-21 |
| KR20200013718A (ko) | 2020-02-07 |
| CA3066946A1 (en) | 2018-12-20 |
| EA202090014A1 (ru) | 2020-05-12 |
| CO2019013823A2 (es) | 2020-01-17 |
| PE20200340A1 (es) | 2020-02-14 |
| JP2020522517A (ja) | 2020-07-30 |
| PH12019502693A1 (en) | 2020-07-13 |
| EP3638680A1 (en) | 2020-04-22 |
| HUE060597T2 (hu) | 2023-04-28 |
| PL3638680T3 (pl) | 2022-12-19 |
| BR112019021703A2 (pt) | 2020-05-12 |
| DK3638680T3 (da) | 2022-09-05 |
| TW201920196A (zh) | 2019-06-01 |
| MA49374A (fr) | 2021-04-21 |
| AU2018285131B2 (en) | 2021-11-11 |
| US10364255B2 (en) | 2019-07-30 |
| AR112086A1 (es) | 2019-09-18 |
| IL271104B (en) | 2022-03-01 |
| ES2927021T3 (es) | 2022-11-02 |
| KR102607934B1 (ko) | 2023-12-01 |
| CN110770242A (zh) | 2020-02-07 |
| US20180354968A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502693A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| PH12020500252A1 (en) | Compounds as modulators of ror gamma | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| SA521422152B1 (ar) | Vanin مركبات عطرية غير متجانسة كمثبطات | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MY195427A (en) | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| SA515360007B1 (ar) | مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk) | |
| TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| MX378732B (es) | Formas solidas novedosas | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| PH12016502568B1 (en) | Novel heterocyclic compound | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| MX2019014436A (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa. | |
| NZ766013A (en) | Vitamin k2 compositions for the treatment of drug induced neuropathy |